A Phase I, Randomized, Single-Center Study to Investigate the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Profiles of Single and Multiple Doses of R924548 in Healthy Human Subjects

Completed

• Conditions: immune-mediated diseases; rheuma; 10003816

• Registration Number: NL-OMON37424
• Lead Sponsor: Rigel Pharmaceuticals, Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 70

Inclusion Criteria

Part A, B and D:
Healthy male volunteers
18-55 years of age
BMI 19.0-31.0 kg/m2;Part C:
Healthy male 18-55 years of age
Healthy post-menopausal/surgically sterile female volunteers 18-65 years of age
BMI 19.0-31.0 kg/m2

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS.
Participation in another drug study within 3 months before the start of this study.
Blood donation within 3 months from the start of this study or in case you have donated more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months before the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified